NO2280721T3 - - Google Patents

Info

Publication number: NO2280721T3
Authority: NO; Norway

Application number

NO09753556A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-17

Filing date

2009-04-17

Publication date

2018-04-14

2009-04-17 Application filed filed Critical

2018-04-14 Publication of NO2280721T3 publication Critical patent/NO2280721T3/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO09753556A 2008-04-17 2009-04-17 NO2280721T3 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200800565		2008-04-17
PCT/DK2009/000095 WO2009143843A1 (en)	2008-04-17	2009-04-17	Indoleamine 2, 3-dioxygenase based immunotherapy

Publications (1)

Publication Number	Publication Date
NO2280721T3 true NO2280721T3 (no)	2018-04-14

Family

ID=40873320

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO09753556A NO2280721T3 (no)	2008-04-17	2009-04-17

Country Status (20)

Country	Link
US (6)	US9433666B2 (no)
EP (3)	EP3915570A1 (no)
JP (2)	JP2011520783A (no)
CN (2)	CN104056261B (no)
AU (1)	AU2009253539B2 (no)
CA (1)	CA2721150C (no)
CY (2)	CY1120352T1 (no)
DK (2)	DK2280721T3 (no)
ES (2)	ES2870596T3 (no)
HR (2)	HRP20180282T1 (no)
HU (2)	HUE037973T2 (no)
IL (1)	IL208781A (no)
LT (2)	LT3320912T (no)
NO (1)	NO2280721T3 (no)
NZ (1)	NZ588757A (no)
PL (2)	PL3320912T3 (no)
PT (2)	PT3320912T (no)
SI (2)	SI2280721T1 (no)
WO (1)	WO2009143843A1 (no)
ZA (1)	ZA201008056B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2870596T3 (es)	2008-04-17	2021-10-27	Io Biotech Aps	Inmunoterapia basada en indolamina 2,3-dioxigenasa
EP2425830A1 (en) *	2010-09-03	2012-03-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) *	2013-09-06	2013-10-23	Immune Targeting Systems Its Ltd	Oncology vaccine
EP3149047A1 (en)	2014-05-29	2017-04-05	Spring Bioscience Corporation	Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
LT3193917T (lt)	2014-09-17	2021-11-25	Io Biotech Aps	Vakcinų kompozicijos, apimančios triptofan-2,3-dioksigenazę arba jos fragmentus
CN106148276A (zh) *	2015-04-16	2016-11-23	中国科学院上海生命科学研究院	间充质干细胞在制备治疗神经退行性疾病的药物中的应用
CA2990299C (en)	2015-06-29	2023-10-10	Ose Immunotherapeutics	Method for inducing early t memory response with short peptides anti-tumor vaccine
IL257940B (en)	2015-09-16	2022-08-01	Herlev Hospital	Vaccines that include the CC motif. Chemokine 22 or fragments thereof
US20190343940A1 (en)	2016-03-04	2019-11-14	Io Biotech Aps	Combination therapy against cancer
CA3026572A1 (en)	2016-06-10	2017-12-14	Io Biotech Aps	Calr and jak2 vaccine compositions
WO2018067660A1 (en) *	2016-10-04	2018-04-12	University Of Florida Research Foundation, Inc.	Targeted effector proteins and uses thereof
DK3526347T3 (da) *	2016-10-14	2021-02-15	Univ Zuerich	Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer
JP2020506901A (ja) *	2017-01-20	2020-03-05	アタラバイオセラピューティクス，インコーポレーテッド	自家ｔ細胞を用いた多発性硬化症の処置方法
EA201991444A1 (ru)	2017-01-27	2019-12-30	Имматикс Байотекнолоджиз Гмбх	Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CR20190388A (es)	2017-01-27	2019-10-16	Immatics Biotechnologies Gmbh	Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
WO2018138257A1 (en) *	2017-01-27	2018-08-02	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2019075062A1 (en)	2017-10-11	2019-04-18	University Of Florida Research Foundation	MODIFIED GAL-1 PROTEINS AND USES THEREOF
US11696936B2 (en)	2017-11-27	2023-07-11	Ose Immunotherapeutics	Treatment of cancer
CN109758467B (zh) *	2019-03-08	2020-12-25	中国农业科学院兰州兽医研究所	一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
KR20220092905A (ko) *	2019-10-23	2022-07-04	더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치	입양 면역요법
CN112881269A (zh) *	2021-02-23	2021-06-01	浙江正熙生物技术股份有限公司	一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en)	2021-03-17	2021-04-28	Io Biotech Aps	Combination therapy for cancer
WO2023161350A1 (en)	2022-02-24	2023-08-31	Io Biotech Aps	Nucleotide delivery of cancer therapy
CN114657158B (zh) *	2022-05-25	2022-10-21	深圳吉诺因生物科技有限公司	Ido1相关疫苗及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US58767A (en)		1866-10-16		John brougjbton
US5554372A (en)	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
WO1997000966A1 (en) *	1995-06-20	1997-01-09	Merck & Co., Inc.	Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
US6096313A (en)	1996-02-09	2000-08-01	Ludwig Institute For Cancer Research	Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
EP0956046A4 (en)	1996-06-12	2004-10-20	Yajun Guo	CELLULAR VACCINALS AND IMMUNOTHERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF
CN1223688A (zh) *	1996-06-27	1999-07-21	纳幕尔杜邦公司	对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) *	1997-07-14	1999-01-21	Basf Ag	DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
US6451840B1 (en)	1997-12-05	2002-09-17	Medical College Of Georgia Research Institute, Inc.	Regulation of T cell-mediated immunity by tryptophan
EP1185687A1 (en)	1999-05-03	2002-03-13	Ludwig Institute For Cancer Research	Methods for increasing t cell proliferation
CA2440703A1 (en)	2001-01-24	2002-08-01	Protein Design Labs, Inc.	Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002071928A2 (en)	2001-03-14	2002-09-19	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2003012061A2 (en)	2001-08-01	2003-02-13	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
US7763251B2 (en)	2002-04-12	2010-07-27	Medical College Of Georgia Research Institute, Inc.	Kits to assess the risk of tumor progression
WO2003087347A1 (en)	2002-04-12	2003-10-23	Medical College Of Georgia Research Institute, Inc.	Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
DE10229872A1 (de) *	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
AU2003298786A1 (en)	2002-11-26	2004-06-18	Protein Design Labs, Inc.	Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060205934A1 (en)	2002-12-05	2006-09-14	Macina Roberto A	Compositions, splice variants and methods relating to breast specific genes and proteins
RU2005122033A (ru)	2002-12-13	2006-01-27	Митра Медикал Текнолоджи Аб (Se)	Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
DE10261223A1 (de)	2002-12-20	2004-07-08	MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH	Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
WO2004094409A1 (en)	2003-03-27	2004-11-04	Lankenau Institute For Medical Research	Novel ido inhibitors and methods of use
US20050186289A1 (en)	2003-04-01	2005-08-25	Medical College Of Georgia Research Institute, Inc.	Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en)	2003-04-01	2009-10-06	Medical College Of Georgia Research Institute, Inc.	Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2005017163A2 (en)	2003-08-15	2005-02-24	Imperial College Innovations Limited	Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en)	2003-10-02	2005-04-21	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
MX2007000457A (es) *	2004-07-13	2007-04-17	Univ British Columbia	Inhibidores de indoleamina 2,3-dioxigenasa (ido).
US20060110371A1 (en)	2004-11-23	2006-05-25	Institut Pasteur	Control of indoleamine 2,3 deoxygenase expression and activity
PL1853305T3 (pl)	2005-02-04	2015-02-27	Survac Aps	Szczepionka na bazie peptydu surwiwina
BRPI0608604B8 (pt)	2005-05-10	2021-05-25	Incyte Corp	moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
US7468186B2 (en)	2005-07-22	2008-12-23	City Of Hope	Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en)	2005-09-21	2005-11-02	Oxford Biomedica Ltd	Chemo-immunotherapy method
EP2340847A3 (en) *	2005-09-23	2016-11-09	Cellerix, S.A.	Cell populations having immunoregulatory activity, method for isolation and uses
US20070203140A1 (en)	2006-02-09	2007-08-30	Combs Andrew P	N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en)	2006-03-30	2007-10-11	Indiana University Research And Technology Corporation	Genetic variants in the indoleamine 2,3-dioxygenase gene
EP2023715B1 (en) *	2006-05-18	2014-01-08	Lankenau Institute for Medical Research	Indoleamine-2, 3-dioxygenase-2
WO2008085828A2 (en) *	2007-01-03	2008-07-17	The Johns Hopkins University	Peptide modulators of angiogenesis and use thereof
ES2870596T3 (es)	2008-04-17	2021-10-27	Io Biotech Aps	Inmunoterapia basada en indolamina 2,3-dioxigenasa

2009
- 2009-04-17 ES ES17194619T patent/ES2870596T3/es active Active
- 2009-04-17 DK DK09753556.1T patent/DK2280721T3/da active
- 2009-04-17 PT PT171946197T patent/PT3320912T/pt unknown
- 2009-04-17 PL PL17194619T patent/PL3320912T3/pl unknown
- 2009-04-17 JP JP2011504314A patent/JP2011520783A/ja active Pending
- 2009-04-17 CA CA2721150A patent/CA2721150C/en active Active
- 2009-04-17 HU HUE09753556A patent/HUE037973T2/hu unknown
- 2009-04-17 NO NO09753556A patent/NO2280721T3/no unknown
- 2009-04-17 CN CN201410247727.XA patent/CN104056261B/zh active Active
- 2009-04-17 PT PT97535561T patent/PT2280721T/pt unknown
- 2009-04-17 EP EP21157371.2A patent/EP3915570A1/en active Pending
- 2009-04-17 SI SI200931791T patent/SI2280721T1/en unknown
- 2009-04-17 US US12/988,124 patent/US9433666B2/en active Active
- 2009-04-17 HU HUE17194619A patent/HUE055338T2/hu unknown
- 2009-04-17 LT LTEP17194619.7T patent/LT3320912T/lt unknown
- 2009-04-17 EP EP17194619.7A patent/EP3320912B1/en active Active
- 2009-04-17 LT LTEP09753556.1T patent/LT2280721T/lt unknown
- 2009-04-17 CN CN200980122844.0A patent/CN102088994B/zh active Active
- 2009-04-17 ES ES09753556.1T patent/ES2657963T3/es active Active
- 2009-04-17 AU AU2009253539A patent/AU2009253539B2/en active Active
- 2009-04-17 WO PCT/DK2009/000095 patent/WO2009143843A1/en active Application Filing
- 2009-04-17 NZ NZ588757A patent/NZ588757A/en unknown
- 2009-04-17 SI SI200932129T patent/SI3320912T1/sl unknown
- 2009-04-17 DK DK17194619.7T patent/DK3320912T3/da active
- 2009-04-17 PL PL09753556T patent/PL2280721T3/pl unknown
- 2009-04-17 EP EP09753556.1A patent/EP2280721B1/en active Active
2010
- 2010-10-17 IL IL208781A patent/IL208781A/en active IP Right Grant
- 2010-11-10 ZA ZA2010/08056A patent/ZA201008056B/en unknown
2015
- 2015-03-17 JP JP2015052888A patent/JP6016966B2/ja active Active
2016
- 2016-08-08 US US15/231,075 patent/US10258678B2/en active Active
2018
- 2018-02-12 CY CY20181100171T patent/CY1120352T1/el unknown
- 2018-02-15 HR HRP20180282TT patent/HRP20180282T1/hr unknown
2019
- 2019-01-29 US US16/261,114 patent/US11324813B2/en active Active
2021
- 2021-05-13 HR HRP20210766TT patent/HRP20210766T1/hr unknown
- 2021-06-28 CY CY20211100572T patent/CY1124279T1/el unknown
2022
- 2022-03-17 US US17/697,732 patent/US20220202922A1/en not_active Abandoned
- 2022-04-15 US US17/721,577 patent/US11648302B2/en active Active
2023
- 2023-04-10 US US18/298,263 patent/US20230233657A1/en active Pending

Also Published As

Publication number	Publication date
JP6016966B2 (ja)	2016-10-26
LT2280721T (lt)	2018-02-12
US9433666B2 (en)	2016-09-06
EP3320912B1 (en)	2021-03-31
CN104056261B (zh)	2017-01-11
AU2009253539B2 (en)	2014-03-20
US20190201512A1 (en)	2019-07-04
CY1120352T1 (el)	2019-07-10
JP2011520783A (ja)	2011-07-21
US20230233657A1 (en)	2023-07-27
IL208781A0 (en)	2010-12-30
PT2280721T (pt)	2018-02-16
SI3320912T1 (sl)	2021-08-31
US20110318372A1 (en)	2011-12-29
NZ588757A (en)	2012-05-25
EP2280721B1 (en)	2017-11-15
AU2009253539A1 (en)	2009-12-03
CN102088994B (zh)	2014-06-25
EP3915570A1 (en)	2021-12-01
CN102088994A (zh)	2011-06-08
PL2280721T3 (pl)	2018-04-30
IL208781A (en)	2017-09-28
EP3320912A1 (en)	2018-05-16
US11324813B2 (en)	2022-05-10
ES2870596T3 (es)	2021-10-27
US20170049868A1 (en)	2017-02-23
EP2280721A1 (en)	2011-02-09
HUE055338T2 (hu)	2021-11-29
ES2657963T3 (es)	2018-03-07
JP2015129182A (ja)	2015-07-16
DK3320912T3 (da)	2021-05-31
US20220202922A1 (en)	2022-06-30
CN104056261A (zh)	2014-09-24
PL3320912T3 (pl)	2021-10-25
US11648302B2 (en)	2023-05-16
HRP20180282T1 (hr)	2018-03-23
LT3320912T (lt)	2021-07-12
CA2721150A1 (en)	2009-12-03
PT3320912T (pt)	2021-05-24
US10258678B2 (en)	2019-04-16
US20220249641A1 (en)	2022-08-11
HUE037973T2 (hu)	2018-09-28
HRP20210766T1 (hr)	2021-07-23
WO2009143843A1 (en)	2009-12-03
DK2280721T3 (da)	2018-01-29
CY1124279T1 (el)	2022-07-22
SI2280721T1 (en)	2018-02-28
ZA201008056B (en)	2011-07-27
CA2721150C (en)	2017-09-26

Publication	Publication Date	Title
BRPI0917573A2 (no)	2017-07-11
BRPI0918697A2 (no)	2017-08-29
BRPI0917525A2 (no)	2017-07-04
BRPI0920750A2 (no)	2016-02-02
BRPI0919470A2 (no)	2017-08-22
BRPI0922455A2 (no)	2021-12-28
BRPI0917618A8 (no)	2019-09-10
BRPI0923734A2 (no)	2017-07-11
BRPI0922669A2 (no)	2017-07-11
BRPI0919811A2 (no)	2017-08-29
BRPI0915616A2 (no)	2016-02-02
BRPI0920914A2 (no)	2017-07-11
BRPI0922550A2 (no)	2016-02-02
BRPI0916284A2 (no)	2017-08-08
NO2280721T3 (no)	2018-04-14
BRPI0914852A2 (no)	2017-08-29
CH2352018H2 (no)	2019-09-13
BRPI0914820A2 (no)	2017-07-11
AR073287B1 (no)	2015-09-23
BRPI0919477A2 (no)	2017-08-29
BRPI0923127A (no)	2010-07-01
BRPI0923137A2 (no)	2010-06-10
CN300881403S (zh)	2009-02-04	瓶贴(15)
CN300888381S (zh)	2009-03-04	壁纸(110)
CN300892323S (zh)	2009-03-18	布(08123-5)